<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01969747</url>
  </required_header>
  <id_info>
    <org_study_id>1245.78</org_study_id>
    <secondary_id>2011-004354-25</secondary_id>
    <nct_id>NCT01969747</nct_id>
  </id_info>
  <brief_title>Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days</brief_title>
  <official_title>A 28-day Randomised, Placebo-controlled, Double-blind Parallel Group Phase IIa Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once Daily Oral Doses of 2.5 mg, 10 mg, and 25 mg Empagliflozin as Adjunctive to Insulin in Patients With Type 1 Diabetes Mellitus (EASE-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Placebo-controlled, double blind (triple-dummy technique), randomised parallel design
      comparison of three oral doses (2.5 mg, 10 mg, and 25 mg) of empagliflozin in patients with
      T1DM as adjunctive therapy to insulin over 28 days. Patients will undergo a 14-day open-label
      placebo run-in period before randomisation. Background insulin therapy will be kept stable
      during the first 7 days of the treatment period and will be freely adjusted thereafter.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in 24 h UGE (g/24 h) After Seven Days of Treatment With Empagliflozin 2.5 mg, 10 mg, or 25 mg, or Placebo</measure>
    <time_frame>baseline (Day -1) and 7 days after first drug administration (Day 7)</time_frame>
    <description>Change of urinary glucose excretion (UGE) (g/24 h) from baseline (refers to the last measurement prior to the first intake of any randomised trial medication) after seven days of treatment with empagliflozin 2.5 mg, 10 mg, or 25 mg, or placebo.
The treatment effect was estimated on the basis of the least square mean treatment difference at Day 7 extracted from the primary analysis model.
The primary endpoint is exploratory.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Empagliflozin low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin low once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin medium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin medium once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin high once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin medium placebo</intervention_name>
    <description>Empagliflozin medium placebo</description>
    <arm_group_label>Empagliflozin high</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin low placebo</intervention_name>
    <description>Empagliflozin low placebo</description>
    <arm_group_label>Empagliflozin medium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin low placebo</intervention_name>
    <description>Empagliflozin low placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin high placebo</intervention_name>
    <description>Empagliflozin high placebo</description>
    <arm_group_label>Empagliflozin medium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin medium</intervention_name>
    <description>Empagliflozin medium</description>
    <arm_group_label>Empagliflozin medium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin medium placebo</intervention_name>
    <description>Empagliflozin medium placebo</description>
    <arm_group_label>Empagliflozin low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin high placebo</intervention_name>
    <description>Empagliflozin high placebo</description>
    <arm_group_label>Empagliflozin low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin high placebo</intervention_name>
    <description>Empagliflozin high placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin medium placebo</intervention_name>
    <description>Empagliflozin medium placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin low placebo</intervention_name>
    <description>Empagliflozin low placebo</description>
    <arm_group_label>Empagliflozin high</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin low</intervention_name>
    <description>Empagliflozin low</description>
    <arm_group_label>Empagliflozin low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin high</intervention_name>
    <description>Empagliflozin high</description>
    <arm_group_label>Empagliflozin high</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Signed and dated written informed consent

          -  Male or female patient receiving insulin for treatment of T1DM for at least 12 months

          -  C-peptide &lt; 1.5 ng/mL

          -  Age 18 to 65 years

          -  HbA1c of 7.5% to 10.5%

          -  Multiple daily injections (MDI) of any type of insulin

          -  Willing to follow an established and individualized carbohydrate counting method and
             an insulin administration algorithm

          -  Body Mass Index of 18.5 to 35.0 kg/m2

          -  Estimated glomerular filtration rate 60 to 150 mL/min/1.73 mÂ²

          -  Able and willing to perform study assessments according to investigator's judgement

          -  Compliance with trial drug administration 80% to 120% during run-in period

          -  Willing not to take any paracetamol containing drugs during the trial

        Exclusion criteria:

          -  Acute symptomatic urinary tract infection or genital infection, chronic or recurrent
             cystitis

          -  History of type 2 diabetes mellitus, maturity onset diabetes of the young (MODY),
             pancreatic surgery or chronic pancreatitis

          -  Pancreas, pancreatic islet cells or renal transplant recipient

          -  Type 1 diabetes mellitus treatment with any other antihyperglycaemic drug except
             insulin within last 3 months or history of clinically relevant hypersensitivity

          -  Occurrence of hypoglycaemia that required hospitalization or treatment by an emergency
             physician or paramedic within last 3 months

          -  Hypoglycaemia unawareness or frequent episodes of unexplained hypoglycaemia

          -  Occurrence of diabetic ketoacidosis that required hospitalization or treatment by an
             emergency physician or paramedic within last 12 months

          -  History of macrovascular disease including cardiovascular, cerebrovascular and
             peripheral artery disease

          -  Autonomic neuropathy with gastroparesis

          -  Brittle diabetes

          -  Liver disease

          -  Treatment with anti-obesity drugs, surgery or aggressive diet regimen leading to
             unstable body weight

          -  Treatment with systemic corticosteroids

          -  Change in dose of thyroid hormones within last 6 weeks or planned change or initiation
             of such a therapy

          -  Medical history of cancer or treatment for cancer in the last five years

          -  Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells

          -  Alcohol or drug abuse that would interfere with trial participation or any ongoing
             clinical condition that would jeopardize patient's or site personnel's safety or study
             compliance

          -  Intake of an investigational drug in another trial within last 30 days

          -  Not able to understand and comply with study requirements

          -  Pre-menopausal women who are nursing or pregnant or of child-bearing potential and are
             not practising an acceptable method of birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.78.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.78.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2013</study_first_submitted>
  <study_first_submitted_qc>October 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2013</study_first_posted>
  <results_first_submitted>March 23, 2015</results_first_submitted>
  <results_first_submitted_qc>April 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 8, 2015</results_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo tablet; oral administration once daily</description>
        </group>
        <group group_id="P2">
          <title>Empagliflozin 2.5 mg</title>
          <description>Empagliflozin 2.5 mg tablet; oral administration once daily</description>
        </group>
        <group group_id="P3">
          <title>Empagliflozin 10 mg</title>
          <description>Empagliflozin 10 mg tablet; oral administration once daily</description>
        </group>
        <group group_id="P4">
          <title>Empagliflozin 25 mg</title>
          <description>Empagliflozin 25 mg tablet; oral administration once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS): all patients randomised, treated with at least one dose of study drug, had a baseline UGE (g/24 h) and a UGE (g/24 h) on Day 1 or Day 7.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo tablet; oral administration once daily</description>
        </group>
        <group group_id="B2">
          <title>Empagliflozin 2.5 mg</title>
          <description>Empagliflozin 2.5 mg tablet; oral administration once daily</description>
        </group>
        <group group_id="B3">
          <title>Empagliflozin 10 mg</title>
          <description>Empagliflozin 10 mg tablet; oral administration once daily</description>
        </group>
        <group group_id="B4">
          <title>Empagliflozin 25 mg</title>
          <description>Empagliflozin 25 mg tablet; oral administration once daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="18"/>
            <count group_id="B5" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.5" spread="10.6"/>
                    <measurement group_id="B2" value="41.9" spread="12.4"/>
                    <measurement group_id="B3" value="39.6" spread="11.6"/>
                    <measurement group_id="B4" value="41.9" spread="9.7"/>
                    <measurement group_id="B5" value="41.0" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in 24 h UGE (g/24 h) After Seven Days of Treatment With Empagliflozin 2.5 mg, 10 mg, or 25 mg, or Placebo</title>
        <description>Change of urinary glucose excretion (UGE) (g/24 h) from baseline (refers to the last measurement prior to the first intake of any randomised trial medication) after seven days of treatment with empagliflozin 2.5 mg, 10 mg, or 25 mg, or placebo.
The treatment effect was estimated on the basis of the least square mean treatment difference at Day 7 extracted from the primary analysis model.
The primary endpoint is exploratory.</description>
        <time_frame>baseline (Day -1) and 7 days after first drug administration (Day 7)</time_frame>
        <population>Full analysis set (FAS): all patients randomised, treated with at least one dose of study drug, had a baseline UGE (g/24 h) and a UGE (g/24 h) on Day 1 or Day 7.
The last observation carried forward (LOCF) approach was used as the primary method of imputation for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet; oral administration once daily</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 2.5 mg</title>
            <description>Empagliflozin 2.5 mg tablet; oral administration once daily</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg</title>
            <description>Empagliflozin 10 mg tablet; oral administration once daily</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg</title>
            <description>Empagliflozin 25 mg tablet; oral administration once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 24 h UGE (g/24 h) After Seven Days of Treatment With Empagliflozin 2.5 mg, 10 mg, or 25 mg, or Placebo</title>
          <description>Change of urinary glucose excretion (UGE) (g/24 h) from baseline (refers to the last measurement prior to the first intake of any randomised trial medication) after seven days of treatment with empagliflozin 2.5 mg, 10 mg, or 25 mg, or placebo.
The treatment effect was estimated on the basis of the least square mean treatment difference at Day 7 extracted from the primary analysis model.
The primary endpoint is exploratory.</description>
          <population>Full analysis set (FAS): all patients randomised, treated with at least one dose of study drug, had a baseline UGE (g/24 h) and a UGE (g/24 h) on Day 1 or Day 7.
The last observation carried forward (LOCF) approach was used as the primary method of imputation for missing data.</population>
          <units>g/24h</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.56" spread="4.27"/>
                    <measurement group_id="O2" value="72.45" spread="7.01"/>
                    <measurement group_id="O3" value="103.33" spread="6.68"/>
                    <measurement group_id="O4" value="101.79" spread="6.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Empagliflozin 2.5 mg with Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean</param_type>
            <param_value>76.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>58.60</ci_lower_limit>
            <ci_upper_limit>93.59</ci_upper_limit>
            <estimate_desc>The model includes baseline UGE as linear covariate(s) and treatment as fixed effect(s).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Empagliflozin 10 mg with Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean</param_type>
            <param_value>106.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.85</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.73</ci_lower_limit>
            <ci_upper_limit>124.05</ci_upper_limit>
            <estimate_desc>The model includes baseline UGE as linear covariate(s) and treatment as fixed effect(s).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of Empagliflozin 25 mg with Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean</param_type>
            <param_value>104.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.88</ci_lower_limit>
            <ci_upper_limit>122.74</ci_upper_limit>
            <estimate_desc>The model includes baseline UGE as linear covariate(s) and treatment as fixed effect(s).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 7 days after last drug administration (Day 35)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo tablet; oral administration once daily</description>
        </group>
        <group group_id="E2">
          <title>Empagliflozin 2.5 mg</title>
          <description>Empagliflozin 2.5 mg tablet; oral administration once daily</description>
        </group>
        <group group_id="E3">
          <title>Empagliflozin 10 mg</title>
          <description>Empagliflozin 10 mg tablet; oral administration once daily</description>
        </group>
        <group group_id="E4">
          <title>Empagliflozin 25 mg</title>
          <description>Empagliflozin 25 mg tablet; oral administration once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

